Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers ; day:13 ; month:3 ; year:2021 ; pages:1-9
Investigational new drugs ; (13.3.2021), 1-9
- Urheber
-
Hou, Ming-Mo
Ho, Ching-Liang
Lin, Hsuan-Yu
Zhu, Yunting
Zhang, Xiaodi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-021-01099-1
- URN
-
urn:nbn:de:101:1-2021050219505150207577
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hou, Ming-Mo
- Ho, Ching-Liang
- Lin, Hsuan-Yu
- Zhu, Yunting
- Zhang, Xiaodi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody
Humanized mice
Humanized mice
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody
Humanized mice
Humanized mice
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody
Humanized mice
Humanized mice
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency